CARM (CARISMA Therapeutics) Interest Expense: $0.00 Mil (TTM As of Sep. 2025)


What is CARISMA Therapeutics Interest Expense?

CARISMA Therapeutics CARM -1.69% Interest Expense is $0.00 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. CARISMA Therapeutics's interest expense for the three months ended in Sep. 2025 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2025 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. CARISMA Therapeutics's Operating Income for the three months ended in Sep. 2025 was $ 43.81 Mil. CARISMA Therapeutics's Interest Expense for the three months ended in Sep. 2025 was $ 0.00 Mil. GuruFocus does not calculate CARISMA Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CARISMA Therapeutics  (OTCPK:CARM) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CARISMA Therapeutics's Interest Expense for the three months ended in Sep. 2025 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2025 was $43.81 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2025 was $0.61 Mil.

CARISMA Therapeutics's Interest Coverage for the quarter that ended in Sep. 2025 is calculated as

GuruFocus does not calculate CARISMA Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. CARISMA Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

CARISMA Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Interest Expense Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Interest Expense
0.00 0.00 -3.15 0.00 0.00

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CARISMA Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $0.00 Mil mean?
CARISMA Therapeutics (CARM) has a Interest Expense of $0.00 Mil as of Sep. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on CARISMA Therapeutics and its competitors.
Is CARISMA Therapeutics' Interest Expense too high?
CARISMA Therapeutics' current Interest Expense is $0.00 Mil.
How does CARISMA Therapeutics' Interest Expense compare to SCPX and CYTOF?
CARISMA Therapeutics' Interest Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current Interest Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current Interest Expense is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Interest Expense is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.